

10/528687  
JC125's'd PCT/PTC 21 MAR 2005  
CASE PN/4-32689A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV52461542745 Express Mail Label Number	March 21, 2005 Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
WOLF ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/10475

FILED: 19 SEPTEMBER 2003

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: MODIFIED RELEASE FORMULATIONS OF OXCARBAZEPINE AND  
DERIVATIVES THEREOF

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/10475, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7960  
Date: March 21, 2005

Respectfully submitted,

  
Edward J. Wilusz, Jr.  
Attorney for Applicants  
Reg. No. 52,370

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTORNEY  
PN/4-328  
APPLICANT NO.  
Not Yet Assigned  
APPLICANT  
WOLF ET AL.  
FILING DATE

Sheet 1 of 1

10/528687  
PCT/PTC 21 MAR 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,296,873	10/2/01	Friedman et al.			
	AB	5,695,782	12/9/97	Bourquin			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 98 35681	8/20/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 01 32183	5/10/01	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 03 101430	12/11/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	ROSCHE J ET AL: "Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study." CLINICAL NEUROPHARMACOLOGY. UNITED STATES 2001 MAR-APR, vol. 24, no. 2, March 2001 (2001-03), pages 113-116, XP009023435 ISSN: 0362-5664
	AS	COLLINS REBECCA J ET AL: "Extended release formulations of anticonvulsant medications: Clinical pharmacokinetics and therapeutic advantages" CNS DRUGS, vol. 14, no. 3, September 2000 (2000-09), pages 203-212, XP009023436 ISSN: 1172-7047
	AT	WALKER M C ET AL: "Clinical pharmacokinetics of new antiepileptic drugs" PHARMACOLOGY AND THERAPEUTICS 1995 UNITED STATES, vol. 67, no. 3, 1995, pages 351-384, XP001156793 ISSN: 0163-7258

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.